Tradestie Institutional Equity Comparison Engine

NSRX vs PLYX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

NSRX Overall Edge

NSRX Captures Institutional Edge (2โ€“0 Pillars ยท 7โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Nasus Pharma Ltd. (NSRX) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, NSRX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus PLYX at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, NSRX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against PLYX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
NSRX N/M vs PLYX N/M Fwd P/E
Growth & Margin Winner NSRX
Op Margin 0.0% vs N/A ยท YoY +0.0% vs N/A
Momentum & Technical Winner NSRX
1Y -66.2% vs -95.7% ยท 52W Pos 8% vs 0%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
NSRX NYSE American
Nasus Pharma Ltd.
Pharmaceutical Preparations
$2.55
-5.56% 1D
Market Cap $31.6M
1M Return -16.67%
1Y Return -66.23%
Forward P/E N/M
Unified AI Score
45.4 / 100 HOLD
Tech 33.0 Fund 54.0 Flow 50.0 Mom 60.0
PLYX US Equity
PLYX
Institutional Equity
$1.51
-6.21% 1D
Market Cap N/A
1M Return -22.16%
1Y Return -95.69%
Forward P/E N/M
Unified AI Score
43.3 / 100 HOLD
Tech 33.0 Fund 52.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: NSRX -66.23% PLYX -95.69% Spread: +42.04 pp (NSRX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
NSRX TTM Op. Margin: 0.0% PLYX TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NSRX vs PLYX. Trailing 12-month operating profitability (NSRX 0.0% vs PLYX N/A) and valuation multiples (NSRX N/M vs PLYX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: NSRX (7) vs PLYX (1)
Institutional Metric NSRX PLYX Criterion Row Winner
Market Capitalization Scale $31.6M N/A Larger Scale NSRX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% N/A Higher Growth NSRX
Operating Margin (TTM) Profitability 0.0% N/A Higher Margin NSRX
Net Profit Margin Profitability 0.0% N/A Higher Margin NSRX
Return on Equity (ROE) Capital Efficiency -316.0% N/A Higher ROE NSRX
52-Week Range Position Momentum 8% ($2โ€“$10) 0% ($2โ€“$49) Stronger Trend NSRX
Beta / 30D Volatility Risk Regime 1.00ฮฒ ยท 69% Vol 1.43ฮฒ ยท 60% Vol Lower Realized Risk PLYX
Unified Institutional Score Composite Signal 45.4 / 100 (HOLD) 43.3 / 100 (HOLD) Higher Composite NSRX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full NSRX vs PLYX Buy Guide
NSRX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live NSRX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
PLYX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live PLYX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither NSRX nor PLYX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.